Our Research
CREDENCE Trial
Sponsor: Janssen
Protocol: 28431754DNE3001 (Phase 3) (non-dialysys)
A randomized Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
ANDES Trial
Sponsor: Fibogen
Protocol: FGCL-4592-060 (non-dialysis)
A phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
SIERRAS Trial
Sponsor: Fibogen
Protocol: FGCL-4592-064 (dialysis)
A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG4592) in the Maintenance Treatment of Anemia in End Stage Renal Disease (ESRD) Subjects on Stable Dialysis.
PRO2TECT Conversion Trial
Sponsor Akebia
Protocol : AKB-6548-CI-0015 (non-dialysis)
Title: Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (ndd-ckd) (pro2tect - conversion)
PRO2TECT - Correction Trial
Sponsor: Akebia
Protocol:AKB-6548-CI-0014 (non-dialysis)
Phase 3, Randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent Chronic Kidney Disease (NDD-CKD).
ASCEND ND (non-dialysis)
Sponsor GSK
Protocol 200808
Title: A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa
ASCEND D
Sponsor GSK
Protocol 200807
A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
COMPASS Trial
Sponsor: Keryx
Protocol: KRX-0502-402 (non-dialysis)
Title: A phase 4 study of krx-0502 (ferric citrate) dose regimens in subjects with non-dialysis dependent chronic kidney disease and iron deficiency anemia: the compass trial.